Skip to main content

Table 5 Results of base case analysis

From: Cost-effectiveness of TAS-102 plus bevacizumab versus TAS-102 monotherapy in patients with metastatic colorectal cancer

 

Total direct medical cost ($)

QALY

Incremental cost ($)

Incremental QALY

ICER($/QALY)

Ref

Monotherapy

3434.834

0.501

Ref

Ref

Ref

–

Combination therapy

8424.188

0.732

4,989.354

0.231

21,553.630

Monotherapy